# PROVIDER BULLETIN PROVIDER INFORMATION



February 27, 2017

## A New Drug, Emflaza (deflazacort), Will Require Prior Authorization

Effective April 17, 2017, Blue Cross and Blue Shield of Minnesota and Blue Plus (Blue Cross) will require prior authorization (PA) for Emflaza (deflazacort) prior to use. Emflaza (deflazacort) is a drug recently approved on February 9, 2017, for treatment of Duchenne muscular dystrophy in patients 5 years of age and older. The criteria for approval is based on FDA approved product labeling. Requests will be reviewed when patient-specific documentation has been provided.

The intent of this PA is to ensure appropriate selection of patients for treatment according to FDA approved product labeling. The Emflaza (deflazacort) PA defines appropriate use as use in patients who have an FDA approved indication, who are receiving the FDA labeled dose, and who do not have any FDA labeled contraindications.

As stewards of healthcare expenditures for our subscribers, we are charged with ensuring the highest quality, evidence based care for our members. One method for doing so is through the prior authorization process. The primary purpose is to ensure that evidence based care is provided to our members, driving quality, safety, and affordability.

#### **Products Impacted**

This PA program applies to commercial lines of business and the following Minnesota Health Care Programs:

- Blue Advantage Prepaid Medical Assistance Program (PMAP)
- Minnesota Senior Care Plus (MSC+)
- MinnesotaCare

The criteria for approval is based on FDA approved product labeling. Drug-specific PA criteria will be developed and posted once available. Medical policy can be accessed using the Blue Cross provider link.

- Access providers.bluecrossmn.com
- Under Tools And Resources, select Medical policy, then acknowledge the Acceptance statement
- Select Utilization Management
- Select Pharmacy Utilization Management

### CoverMyMeds prior authorization request service

As a reminder, CoverMyMeds (CMM) is a free service to providers which allows quick and easy submission of PA requests. Experience with CMM by other plans has demonstrated marked reductions in physician office call-backs regarding PA requests, after CMM is implemented. PA requests may also continue to be faxed to their review destination external to the CMM portal, as is the current practice.

You may access CMM at <a href="www.covermymeds.com">www.covermymeds.com</a>. Select Help (top right of the web page) to view FAQs and Support tutorials (3-5 minutes), including live online chat support to help you get started. You will need to open a CMM account to submit requests using the portal.

#### **Ouestions?**

If you have questions, please contact provider services at (651) 662-5200 or 1-800-262-0820.

Bulletin P6-17

Distribution: All participating providers impacted by the information. <a href="https://www.bluecrossmn.com/healthy/public/personal/home/providers/forms-and-publications">https://www.bluecrossmn.com/healthy/public/personal/home/providers/forms-and-publications</a>